PRACOM1: Study of Emotion and Cognition Abilities of Children With PWS and Proposition of an Innovative Remediation

Sponsor
University Hospital, Toulouse (Other)
Overall Status
Recruiting
CT.gov ID
NCT04526379
Collaborator
(none)
60
1
2
27.7
2.2

Study Details

Study Description

Brief Summary

The present project project is divided in two parts. The primary aim of the part 1 of this study is to evaluate emotional control abilities of children with Prader-Willi syndrome (PWS) aged from 9 to 15 years and to study repercussions of this supposed lack of abilities on cognitive capacities and behavioral troubles. The study also evaluate influence of the emotional symptomatology of patients on quality of parents' life and on the care of parents and scholar/institutional caregivers. In the second part of this study, the study evaluate the feasibility and the tolerance to a non-invasive device supposed to reduce emotional symptoms in this disease.

Condition or Disease Intervention/Treatment Phase
  • Behavioral: Questionnaires
  • Device: t-VNS
N/A

Detailed Description

Prader-Willi Syndrome (PWS) is a rare genetic disorder involving a variety of clinical, behavioral and cognitive symptoms. 83 to 97% of patients have episodes of temper tantrum, associated with an important emotional lability. These different cognitive and behavioral limitations are barriers to the social integration of patients. The PWS also has repercussions on well-being and quality of life of the family. Thus, the present project focuses on the characteristics of emotional control related to the anger of children with PWS and its behavioral, cognitive and social implications. In addition, at a therapeutic level, our project assumes that transcutaneous electrical nerve stimulation (t-VNS), a non-invasive, safe and inexpensive method, could be effective in reducing the severity of behavioral disorders such as temper tantrums while improving cognitive performance and social communication in the PWS.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
60 participants
Allocation:
Non-Randomized
Intervention Model:
Parallel Assignment
Intervention Model Description:
The study consists of 2 parts. The first part compares 30 children with PWS compared to 30 control children without PWS. The second part will be based on 12 children with PWS who have undergone part 1.The study consists of 2 parts. The first part compares 30 children with PWS compared to 30 control children without PWS. The second part will be based on 12 children with PWS who have undergone part 1.
Masking:
None (Open Label)
Primary Purpose:
Other
Official Title:
Communication in Prader-Willi Syndrome: Study of Emotional Control Related to Behavioral Disorders, Their Daily Repercussions and Examination of an Innovative Therapy: Transcutaneous Electrical Nerve Stimulation of the Vagus Nerve - PRACOM1
Actual Study Start Date :
Sep 7, 2020
Anticipated Primary Completion Date :
Dec 7, 2020
Anticipated Study Completion Date :
Dec 30, 2022

Arms and Interventions

Arm Intervention/Treatment
Experimental: children with PWS

Evaluation of cognitive abilities of children with PWS by several cognitive tasks and neuropsychological tests.

Behavioral: Questionnaires
Evaluation of behavioral disorders of children with PWS by questionnaires

Device: t-VNS
Evaluation of the influence of 6 month-stimulation by t-VNS on emotional, cognitive, and behavioral/clinical characteristics of 12 children with PWS on 30 PWS patients included.

Other: non affected children

Evaluation of cognitive abilities of children with PWS compared to a non-pathologic population of children by several cognitive tasks and neuropsychological tests

Behavioral: Questionnaires
Evaluation of behavioral disorders of children with PWS by questionnaires

Outcome Measures

Primary Outcome Measures

  1. assessment of the level of emotional control [day 0]

    composite score of emotional control level of children with PWS composed of scores of emotional lability

Secondary Outcome Measures

  1. Evaluation of behavioral disorders of children with PWS by CBCL (Child Behavior Checklist) scale [month 6]

    CBCL (Child Behavior CheckList) scale: is a questionnaire comprising 1) an adaptive functioning scale (activities, social and school spheres), 2) a syndrome scale (social withdrawal, anxiety / depression, somatic complaints, social problems, thinking problems, attention problems, behavior problems and aggressiveness; total of internalized problems and total of externalized problems), 3) a DSM-oriented scale (Lengua et al., 2001; anxiety, attention problems / hyperactivity, behavior problems, depression, opposition / mistrust, social problems / immaturity, somatization). (duration = 20 ') - there is no minimum and maximum values as this is an evaluation of behavioral disorders

  2. Evaluation of behavioral disorders of children with PWS by Hyperphagia Questionnaire [month 6]

    HQ-CT (Hyperphagia Questionnaire) scale: The HQ-CT (Hyperphagia Questionnaire for Use in Prader-Willi Syndrome Clinical Trials, Fehnel et al., 2015, appendix 10) is a scale derived from the Dykens hyperphagia questionnaire (Dykens et al., 2007). The specificity of the Dykens questionnaire makes it a favored tool in the international literature in the evaluation of the eating behavior of patients with PWS (Crain, 2010). The HQ-CT was created specifically to assess the eating behavior of these patients in clinical trials. It consists of 9 items for which a person taking care of the patient (family or caregiver) indicates the frequency and severity of the behavior described on a 5-point Likert scale (with 1 = absence of the behavior and 5 = very frequent behavior or severe) (⍺ = .91). (duration = 5 ') - so 1 is the minimum value and 5 the maximum value and higher scores mean a worse outcome

  3. Evaluation of cognitive abilities of children with PWS [2 days]

    emotional language task

  4. Test of evaluation of cognitive abilities [2 days]

    multimodal emotional recognition test MERT

  5. Evaluation of cognitive abilities [2 days]

    WISC-V

Eligibility Criteria

Criteria

Ages Eligible for Study:
9 Years to 15 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
Yes
Inclusion Criteria:
  • Age from 9 to 15 years old

  • Prader-Willi syndrome with identified genotype.

  • No psychiatric disorder neither PWS.

  • Severe global symptomatology attested by a CGI-S score

Exclusion Criteria:
  • Identified psychiatric or behavioral disorders

  • Severe visual or hearing impairment.

  • Sleep apnea syndrome treated with non-invasive ventilation,

  • Epileptic seizures

  • Cardiac disorders.

Contacts and Locations

Locations

Site City State Country Postal Code
1 University Hospital Toulouse France

Sponsors and Collaborators

  • University Hospital, Toulouse

Investigators

  • Principal Investigator: Maithé TAUBER, MD, University Hospital, Toulouse

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
University Hospital, Toulouse
ClinicalTrials.gov Identifier:
NCT04526379
Other Study ID Numbers:
  • RC31/18/0335
First Posted:
Aug 25, 2020
Last Update Posted:
Nov 3, 2020
Last Verified:
Nov 1, 2020
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by University Hospital, Toulouse
Additional relevant MeSH terms:

Study Results

No Results Posted as of Nov 3, 2020